COSTA MESA, Calif.,/Ireach-PRNewswire/–California CRO WCCT Global was recently featured in a publication regarding the successful results from a completed immunology clinical trial hosted at the company’s multi-phase CPU in Costa Mesa, CA. Unlike most other clinical research sites, WCCT ensures that a board-certified specialist in the therapeutic area of focus is assigned to serve as the PI or Sub-PI of each program. It is through this policy that WCCT ensures a greater understanding for the patient population and can provide better safety, oversight, and guidance into clinical conduct.
WCCT took part in a Phase 3, multi-site immunology clinical trial for patients with Primary Immunodeficiency Diseases (PIDD). WCCT was able to successfully enroll patients at their Phase I-IV clinical pharmacology unit and make valuable contributions to the success of that program. The results of this program have been published in the May 2016 issue of Journal of Clinical Immunology, under the title “Long-Term Tolerability, Safety, and Efficacy of Recombinant Human Hyaluronidase-Facilitated Subcutaneous Infusion of Human Immunoglobulin for Primary Immunodeficiency.” The results concluded that long-term replacement therapy with IGHy was safe and effective in over 80 pediatric and adult subjects with PIDD.
WCCT Global’s President, Jon Rojas, had this to say about the company’s role in these successful programs: “I strongly feel that our ability to make meaningful contributions to research programs in a variety of diseases is a result of our commitment to being therapeutically better than other CROs and research sites. There is a true value in assigning a board-certified specialist to act as the PI or sub-PI for a program, as opposed to a PI with no therapeutic focus. Thus, WCCT has greater flexibility in the types of programs we can take on and conduct, surpassing the expectations of our clients.” WCCT looks to continue its work in multiple therapeutic areas both as a CRO and at its multiple research sites across the Southern California region.